ADReCS

Pharmaceutical Information

Drug Name	Lithium carbonate
Drug ID	BADD_D01303
Description	Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage	Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder[FDA Label].
Marketing Status	approved
ATC Code	Not Available
DrugBank ID	DB14509
KEGG ID	D00801
MeSH ID	D016651
PubChem ID	11125
TTD Drug ID	D04UUH
NDC Product Code	31722-546; 62332-148; 62756-430; 63187-304; 64980-205; 68462-221; 70518-0608; 70518-2312; 70518-2345; 70518-3565; 72789-171; 72789-172; 31722-544; 62332-014; 68071-2714; 0054-8531; 46708-303; 55154-4920; 63629-1916; 0378-1450; 70518-0668; 70518-3681; 0054-4527; 62332-013; 68462-220; 68462-222; 68462-223; 70518-0437; 70518-2699; 68084-655; 70518-1434; 0054-2531; 71335-0120; 0054-8528; 0615-8302; 50090-3917; 58118-0545; 0054-8526; 51079-142; 63629-1917; 68462-224; 71610-557; 72789-173; 39345-5104; 46708-305; 0378-1300; 64980-278; 70518-1753; 70518-2086; 0054-2526; 31722-545; 50090-1470; 62332-015; 62559-280; 0054-0020; 68428-481; 0054-2527; 72789-174; 82388-001; 46708-148; 50090-6052; 64117-256; 0054-0021; 68084-640; 70518-0904; 70518-1481; 0054-8527; 66039-947; 73309-248; 23155-763; 42291-496; 43063-901; 46708-304; 51079-180
UNII	2BMD2GNA4V
Synonyms	Lithium Carbonate \| Carbonate, Lithium \| Dilithium Carbonate \| Carbonate, Dilithium \| Lithane \| Lithium Bicarbonate \| Bicarbonate, Lithium \| Lithobid \| Lithonate \| CP-15,467-61 \| CP 15,467 61 \| CP15,46761 \| Micalith \| NSC-16895 \| NSC 16895 \| NSC16895 \| Priadel \| Quilinorm-retard \| Quilinorm retard \| Quilinormretard \| Eskalith \| Lithotabs

Chemical Information

Molecular Formula	CLi2O3
CAS Registry Number	554-13-2
SMILES	[Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Body temperature increased	13.15.01.001	-	-	-
Bradycardia	02.03.02.002	0.002142%		-
Breast engorgement	18.08.02.001; 21.05.05.002	0.000535%		-
Bundle branch block left	02.03.01.007	0.001071%		-
Bundle branch block right	02.03.01.011	0.000803%		-
Cardiac arrest	02.03.04.001	0.002142%
Cardiac failure acute	02.05.01.005	0.000535%		-
Cardio-respiratory arrest	02.03.04.002; 22.02.06.007	0.001071%		-
Cardiogenic shock	02.05.01.003; 24.06.02.006	0.000535%		-
Cataract	06.06.01.001	-	-
Catatonia	19.11.01.001	0.001071%		-
Cerebellar atrophy	17.11.01.008	0.000535%		-
Cerebellar syndrome	17.02.02.002	0.001071%		-
Cerebral atrophy	17.11.01.001	0.000535%		-
Chest discomfort	02.02.02.009; 08.01.08.019; 22.12.02.002	-	-	-
Chest pain	02.02.02.011; 08.01.08.002; 22.12.02.003	0.001606%		-
Choking	22.12.03.003	0.000535%		-
Choreoathetosis	17.01.01.003	0.000803%		-
Clonus	17.02.05.002	0.000535%		-
Cogwheel rigidity	15.05.04.006; 17.01.05.001	-	-	-
Coma	17.02.09.001	0.001606%		-
Completed suicide	08.04.01.010; 19.12.01.001	0.002409%		-
Condition aggravated	08.01.03.004	0.001874%		-
Confusional state	17.02.03.005; 19.13.01.001	0.006157%
Constipation	07.02.02.001	0.001606%
Coordination abnormal	17.02.02.004	-	-	-
Coronary artery disease	02.02.01.001; 24.04.04.006	0.000535%		-
Creatinine renal clearance decreased	13.13.01.013	-	-	-
Crying	08.01.03.005; 12.02.11.001; 17.02.05.013; 19.04.02.002	0.000803%		-
Dehydration	14.05.05.001	0.004015%

The 2th Page First Pre 2 3 4 5 6 Next Last Total 11 Pages